ABEC Supporting Ology Bioservices COVID-19 Therapeutic Manufacturing Programs ABEC delivering stainless steel and CSR single-use process systems to rapidly increase capacity Bethlehem, PA, USA, October 21, 2020 – ABEC, a leading global provider of integrated solutions and [...]
Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland. The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award.
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.
ALACHUA, Fla. – June 25, 2020 – Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract to advance development of a cocktail of anti-botulinum neurotoxin monoclonal antibodies (mAb) by the Department of Defense (DOD) through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The contract ceiling value is $42.6 million.
Ology and Just - Evotech Collaborate to Develop Antibodies Against Coronavirus
Partnership is part of a contract awarded to Ology Bioservices by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention of infection with Sars-CoV-2
Just – Evotec Biologics to supply antibody screening and analytical characterization of anti-covid-19 antibodies
The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices Inc...
Nanotherapeutics, Inc., a company focused on advanced development and manufacturing, today announced that the Company’s proprietary bone void filler product, NanoFUSE® DBM (demineralized bone matrix), has received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use in spinal fusion surgery. Specifically, NanoFUSE® DBM has been cleared for use with autograft (transplanted bone from a patient’s own body) as a bone graft extender in the posterolateral spine.
A key challenge in testing and developing new therapies to combat the Ebola virus involves producing sufficient quantities of candidate treatments to conduct clinical trials and then to facilitate commercial scale-up for any product demonstrating effectiveness. Clinical trials are being launched for several promising Ebola therapies and vaccines, and successful results will require massive efforts to produce the millions of doses needed to treat and prevent further spread of the virus.
As we continue to avoid the spread of COVID-19, a novel coronavirus that has challenged our routine life for the past year, I wanted to inform you of the steps taken to protect our staff, our operations, and importantly all ongoing projects at Ology Bioservices during this time. We continue to be prepared to service our clients during this time of uncertainty. In order to protect our employees and facility, and to keep projects moving forward, the following activities continue to be implemented:
Increased our supplies of commonly used laboratory and manufacturing materials, well in advance of the declaration of a pandemic.
Creation of a New Visitor Policy at all locations to further protect the facilities and employees.
Permitting only service personnel, vendors, and contractors on site for highly specialized activities.
Donning face masks and sanitizing hands for all persons entering our facilities.
Requiring social distancing for all personnel.
Requiring health screening for all persons entering our facilities.
Expanded our IT structure to allow employees with the ability to “work from home” wherever possible.
Cancelled business travel for all employees of Ology Bioservices.
Cancelled or rescheduled larger meetings or gatherings.
There will continue to be no disruption in communicating with Ology Bioservices personnel, and our offices will remain open. However, the limited number of personnel physically at our locations will mainly consist of those involved in supporting the process development and manufacturing of our customer’s biological products. Be assured that you will be able to reach all employees through their direct phone lines and email regardless of their location during this crisis.
The entire leadership team at Ology Bioservices remain committed to the health and safety of our employees, as well as committed to the customers we serve. This nation has a history of strength and resilience, and I am certain that together we will successfully navigate these challenges.